Skip to content
★ Sign in to follow
AP

Aurisco Pharmaceutical Co.,Ltd. Stock: price and insider trades · China

奥锐特

CN·Mcap CN¥7.5BHealth Care

Aurisco Pharmaceutical Co.,Ltd.: what insiders have been doing

Aurisco Pharmaceutical Co.,Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SSE / SZSE (CSRC). Over the twelve months to 4 November 2026, 4 filings were filed, from 2 insiders.

All open-market trades in the period are sales: 4 sales worth €2.8M, by 2 insiders, with no purchase on record. 褚义舟 filed the largest sale, €1.6M, on 10 March 2026.

Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. The shorter that gap, the sooner other investors can see what insiders have done. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

For context, the typical company on the same exchange (median of 517 companies) published 2 filings over the same period, against 4 filings here. Looking back to 2022, when coverage begins, insiders filed no purchases and 12 sales.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.

Insider Decl.
12
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€6M
12 ops. · all time

Who traded when

BuySale
褚义舟3 sales
邱培静2 sales
赵珍平1 sale

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 6,630 of 26,911 companies
64.4
score / 100
Value
52
Quality
77
FCF yld1.0%
Earn yld6.0%
EV/EBITDA12.4x
ROE15%
Gross mgn60%
Net mgn26%
Debt/EBITDA1.4x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥18.38
Analyst consensus
·
Income statement
RevenueCN¥1.7B
Gross profitCN¥1B60% margin
EBITDACN¥679M40% margin
Net incomeCN¥449.2M21.9% margin
Valuation
PER (trailing)20.2x
P/Book2.8x
Beta-0.37
Balance sheet & cash
Market capCN¥7.5B
Total debtCN¥976.3M
Free Cash FlowCN¥71.4M
Debt / Equity36%
Profitability & ownership
ROE14.6%
ROA7.5%
% insiders79.0%
% institutions1.0%
Last declaration on 10 March 2026
Declarations12 total
  • ▼
    董事Executives
    13M CNY13SSE
    520,000 shares58.1% of flowA股XSHGSSE:273000000241456100
  • ▼
    董事Executives
    7M CNY10SSE
    285,000 shares32.9% of flowA股XSHGSSE:273000000238986200
  • ▼
    董事Executives
    2M CNY8SSE
    80,000 shares8.9% of flowA股XSHGSSE:273000000231958000
  • ▼
    高级管理人员Executives
    131,100 CNY19SSE
    5,700 shares100.0% of flowA股XSHGSSE:173000009751828350
  • ▼
    董事Executives
    8M CNY11SSE
    390,300 shares35.7% of flowA股XSHGSSE:173000008335682300
  • ▼
    董事Executives
    5M CNY9SSE
    248,800 shares22.9% of flowA股XSHGSSE:173000008329128000
  • ▼
    董事Executives
    5M CNY9SSE
    220,000 shares20.5% of flowA股XSHGSSE:173000008314110430
  • ▼
    董事Executives
    1M CNY8SSE
    56,600 shares5.3% of flowA股XSHGSSE:173000008302016480
  • ▼
    董事Executives
    4M CNY9SSE
    164,800 shares15.5% of flowA股XSHGSSE:173000008298643940
  • ▼
    董事Executives
    14,938 CNY7SSE
    700 shares0.1% of flowA股XSHGSSE:173000008295176220
  • ▼
    监事Executives
    37,680 CNY11SSE
    1,600 shares35.1% of flowA股XSHGSSE:173000005982112930
  • ▼
    监事Executives
    71,370 CNY13SSE
    3,000 shares64.9% of flowA股XSHGSSE:173000005982112900

12 of 12 declarations

About Aurisco Pharmaceutical Co.,Ltd.

奥锐特 is a company operating in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and commercialization of innovative pharmaceutical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations